Treatment of acute relapses in multiple sclerosis at home with oral dexamethasone: A pilot study

Journal of Clinical Neuroscience

Volumn 6, Issue 5, 1999, Pages 382-384

  De Keyser, Jacques ^a   Zwanikken, Cornelis ^a   Zorgdrager, Anneke ^a   Oenema, Dettie ^a   Boon, Maartje ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Corticosteroids; Dexamethasone; Home treatment; Multiple sclerosis; Relapses

Indexed keywords

EID: 10644268651     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(99)90031-0     Document Type: Article

References (14)

1. Durelli L, Cocito A, Riccio A et al. High dose intravenous methylprednisolone in the treatment of multiple sclerosis. Clinical-immunologic correlations. Neurology 1985; 36: 238-243.
2. Milligan NG, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. clinical effects. J Neurol Neurosurg Psychiatry 1986; 50: 511-516.
3. Myers LW, Ellison GW. The peculiar difficulties of therapeutic trials for multiple sclerosis. Neurol Clin 1990; 8: 119-141.
4. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219-1220.
5. Barnes D, Hughes RAC, Morris RW et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-906.
6. La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 1994; 34: 199-203.
7. Brophy TRO'R, McCafferty J, Tyrer JH, Eadie MJ. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur J Clin Pharmacol 1983; 24: 103-108.
8. Tsuei SE, Moore RG, Ashley JI, McBride WG. Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 1979; 7: 249-264.
9. Poser CW, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
11. Barnes D, Hughes RAC. Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis (Reply). Lancet 1997; 349: 1697.
12. De Keyser J, Zwanikken C. Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis. Lancet 1997; 349; 1696.
13. Barnes MP, Bateman DE, Hartman AP, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985; 48; 157-159.
14. Miller DH, Thompson AJ, Morrissey SP et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence of a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450-453.